Dr Anissa Widjaja (Senior Research Fellow) and Professor Stuart Cook (CVMD Programme Director) A team of researchers led by Duke-NUS Medical School and National Heart Centre Singapore (NHCS) found that deactivating a specific protein − interleukin 11 (IL11) – with drugs called therapeutic antibodies, reverses inflammation and scarring of the liver in patients suffering from an untreatable type of fatty liver disease called non-alcoholic steatohepatitis (NASH). The findings,1 published in the top journal for liver and gut diseases, Gastroenterology, have implications for the development of drugs to treat the disease. Fatty liver disease is very common in Singapore and affects approximately one in four people around the world. People with diabetes and obesity are particularly at risk. Fatty liver disease can progress to cause liver inflammation, fibrosis and NASH, which increases the risk of liver failure. There is currently no treatment for fatty liver disease and NASH, and drugs tested in patients thus far have failed to work. Read more>> Source: Duke-NUS https://www.duke-nus.edu.sg/about/media/newsroom/detail/index/translational-research-led-by-singapore-scientists-uncovers-new-treatment-for-fatty-liver-disease?fbclid=IwAR0eW3NF-Xgxppmy15zhgF4r_DhGmYU-yZkA6buXbVMZZj5CeNuIsZc_M-I The Straits Times https://www.straitstimes.com/singapore/health/local-researchers-developing-antibodies-to-cure-non-alcoholic-fatty-liver-disease Gastroenterology DOI: 10.1053/j.gastro.2019.05.002
To enjoy the full experience, please upgrade your browser